Dynamin-related protein 1 (Drp1), a dynamin-related GTPase, is a key regulator of mitochondrial fission. Although recent studies have shown that Drp1 plays important roles in various important cellular processes, such as maintaining proper mitochondrial function, apoptosis and necrosis, the potential involvement of Drp1 in cancer development has not been fully addressed. To explore the role of Drp1 in cancer, we examined Drp1 levels in various human cancer tissues. Tissue array analysis showed that the level of Drp1 was decreased significantly in malignant colon and lung cancer tissues, whereas no change in Drp1 was observed in breast and prostate tumors. Pairwise comparisons of cancer tissue and adjacent normal tissue from colon and lung cancer patients further confirmed decreases in Drp1 expression of 75% in colon cancer patients and 78% in lung cancer patients. Moreover, Drp1 levels were decreased further with advanced grade in both colon and lung cancers, suggesting that loss of Drp1 is associated with the progression of human lung and colon cancer. Consistent with this observation, knockdown of Drp1 increased cellular migration activity in human lung cancer cells and tumor formation in a xenograft tumor model. Taken together, these results suggest that the loss of Drp1 expression could contribute to the development of human lung and colon cancers.
Introduction
Dynamin-related protein 1 (Drp1/DNM1L) is a dynamin-related GTPase and was recently revealed as a critical regulator of mitochondrial dynamics [1] . Mitochondria exist as a mixed structure of an interconnected network with fragmented form and constantly undergo fusion and fission processes. Mitochondrial fission is required for mitochondrial transport through the cytoskeleton, proper separation during cell division, and removal of damaged mitochondria through mitophagy [2] . The precise coordination of mitochondria fusion and fission is essential for maintaining healthy mitochondrial function in the cell [2, 3] . Given the important role of mitochondria in many cellular and physiological functions, including energy generation, metabolism, calcium signaling, and cell death, it is not surprising that aberrations in mitochondrial dynamics are associated with many human disorders, including aging, neurodegenerative diseases, and cancer [4] [5] [6] .
While classic dynamin is involved in membrane scission during vesicle formation from various intracellular compartments such as the plasma membrane, endoplasmic reticulum, and Golgi apparatus, Drp1 functions in membrane remodeling in mitochondria [7, 8] . Although the majority of Drp1 is located in the cytosol, Drp1 is recruited to the mitochondrial outer membrane through interactions with other adaptor proteins, including mitochondrial fission factor (MFF), mitochondrial dynamics proteins of 49 and 51 kDa (MiD49 and MiD51), and fission 1 (FIS1) [9] . Subsequent Drp1 polymerization around the mitochondria and GTP hydrolysis facilitate mitochondrial division. The GTPase activity and translocation of Drp1 are regulated through various modifications such as phosphorylation, ubiquitination, S-nitrosylation, and SUMOylation [1] , implying that the control of Drp1 function is a critical step in maintaining mitochondrial dynamics.
Recent studies have demonstrated that Drp1 function is closely related to various cellular functions and human disorders. In addition to its role in regulating mitochondrial fission, Drp1 has been implicated in mitochondrial outer membrane permeabilization and apoptosis [10] . Under stress conditions, Drp1 rapidly induces excessive mitochondrial fragmentation and facilitates apoptosis [11] . Although the role of Drp1 in apoptosis appears to vary depending on cell type, direct or indirect inhibition of Drp1 activity suppresses cell death and improves survival rates [12] [13] [14] . The loss of Drp1 in mice causes embryonic lethality, and Drp1 knockout (KO) embryos are smaller than wild-type embryos, suggesting the involvement of Drp1 in development and differentiation [15, 16] . Heart-specific Drp1 KO mice showed impaired heart function and died within 13 weeks due to defects in mitochondrial autophagy [17] . Spontaneous mutation of Drp1 causes developmental defects in the brain and eyes in humans [18] . Moreover, Drp1 inhibition by the P110 peptide inhibitor enhances neuronal survival in a mouse Parkinson's disease model by inhibiting apoptosis [19] . These studies suggest that maintaining Drp1 activity is important for normal cellular function and that dysregulation of Drp1 may result in not only an imbalance of mitochondrial dynamics but also various abnormalities of cell growth and function. In addition, the heterogenetic outcomes of Drp1 loss indicate that the physiological roles of Drp1 vary depending on cell type and physiological context.
Although several recent studies have suggested that Drp1 is involved in human cancer [20, 21] , the exact role of Drp1 in tumorigenesis remains unclear. Elucidating the relationship between changes in Drp1 protein levels and tumorigenesis requires an examination of Drp1 protein levels in human cancers. In this study, we examined the protein level of Drp1 in various human cancers using a human cancer patientderived tissue array. Interestingly, quantitative analysis revealed that Drp1 levels were decreased in lung and colon cancer patients. In addition, loss of Drp1 promoted the migration activity of cancer cells and tumor formation in an animal model.
Materials and Methods

Tissue array and Drp1 immunofluorescence staining analysis
A human tissue microarray (TP241) for the top four types of carcinoma (colon, breast, lung, and prostate), a colon cancer and matched adjacent tissue array (CO481), and a lung cancer and matched adjacent tissue array (LC1005) were purchased from US Biomax, Inc. (Rockville, USA) and utilized according to the manufacturer's suggested protocol. Information on cancer grade was used as provided by the manufacturer. Grades I, II, and III in pathology diagnosis are equivalent to well-differentiated, moderately differentiated, and poorly differentiated tissues, respectively. Immunofluorescence staining for Drp1 was performed on the tissue microarray slides as described previously [22] . Briefly, all tissue microarray slides were deparaffinized and rehydrated through a series of xylene baths and a series of graded alcohol solutions, respectively. To enhance immunoreactivity, microwave antigen retrieval was performed at 750 W for 10 min in citrate buffer (10 mM, pH 6.4). The sample was blocked with 10% normal horse serum in PBS in a humidified chamber for 1 h at room temperature and then incubated with anti-Drp1 antibody (BD Bioscience, San Jose, USA) at a 1:200 dilution at 4°C overnight. After washing with PBS, the slides were incubated with FITC-conjugated anti-mouse IgG (Bethyl Laboratories, Montgomery, USA) for 2 h at room temperature in the dark. The slides were then mounted and observed using a Zeiss LSM700 confocal microscope (Carl Zeiss, Oberkochen, Germany) and EC Plan-Neofluar 20×/0.50 M27. At least three Drp1 immunofluorescence images were captured for each tissue core, and all images were acquired using the same settings. Immunofluorescence intensities were quantitated using ZEN (blue edition) software (Carl Zeiss), and the results are presented as the mean and standard deviation.
Cell culture and generation of Drp1 knockdown cell lines A549 human lung cancer cells and EJ human bladder carcinoma cells were maintained in DMEM containing 10% fetal bovine serum (FBS; JR Scientific Inc., Woodland, USA).
To generate EJ cell lines in which Drp1 expression was knocked down, the pREP4-shDrp1 plasmid encoding shRNA targeting Drp1 or the control pREP4-shGFP plasmid (kindly provided by Dr. SeonYong Jeong of Ajou University) [23] was transfected into EJ cells using Lipofectin reagent (Invitrogen, Carlsbad, USA), and the cells were selected with 300 μg/ml hygromycin B (Invitrogen). The resultant colonies were pooled for subsequent experiments. To create A549 cell lines harboring knockdown of Drp1, the same shDrp1 oligonucleotides [23] was subcloned into pLKO.1 lentivirus plasmid (Invitrogen). The construct pLKO.1-shDrp1 or the non-targeting shRNA construct pLKO.1-shNT was transfected into 293FT packaging cells, and the cell-free viral supernatants were used to infect A549 cells. After puromycin selection, resistant cells were pooled and used for the remaining experiments.
Western blot analysis and antibodies
Cells were lysed with RIPA buffer and subject to western blot analysis as described previously [22] . Antibodies for Drp1 were obtained from BD Biosciences. Levels of actin were monitored as an internal loading control using anti-actin antibodies (Sigma, St Louis, USA). Band intensities were quantified using densitometry and AlphaEaseFC 4.0 software (Alpha Innotech Corp., San Leandro, USA). Relative band intensities were calculated by normalizing the band intensities for the untreated samples to that of the actin signal.
MitoTracker staining
Cells were cultured on glass coverslips and stained with 100nM MitoTracker Red CMXRos (Invitrogen). Cells were subsequently fixed in media containing 3.7% formaldehyde, and images of the stained cells were captured using an LSM710 confocal microscope (Carl Zeiss).
In vitro migration and invasion assays
Cell migration and invasion assays were performed as described previously [22] . Cell migration was analyzed in multi-well chambers. The cells were detached using trypsin-EDTA and washed three times with serum-free medium. A suspension of 1 × 10 5 cells in 25 μl of serum-free medium was placed into the upper chamber, which was separated from complete culture media in the bottom chamber by 8-μm pore polyethylene terephthalate membrane filters (Neuro Probe, Inc., Gaithersburg, USA). After incubation for 18 h, non-migrated cells were carefully removed using a cotton swab. The migrated cells on the undersurface of the filter were fixed and stained with hematoxylin (Sigma). The stained cells from three randomly chosen fields (100×) were photographed and counted. The cell invasion assay was performed in Boyden chambers with Matrigel-precoated 8-μm pore filter inserts (Costar, Corning, USA).
A suspension of 1 × 10 5 cells in 100 μl of medium was added to the upper chamber with the filters precoated with Matrigel (BD Biosciences). After 18 h of incubation, the cells on the undersurface of the membrane were fixed and stained with hematoxylin and eosin (H&E). The stained cells from three randomly chosen fields (100×) were photographed and counted.
Tumor xenograft assay
Five-to six-week-old BALB/c NOD/SCID mice were purchased from the Animal Laboratory of the Korea Research Institute of Bioscience and Biotechnology (Daejeon, Korea) and maintained under pathogenfree conditions. All procedures were performed according to the protocol (DIACUC-14-39) approved by the Dong-A Institutional Animal Care and Use Committee. A suspension of 2 × 10 6 EJ-shGFP or EJshDrp1 cells in 100 μl of PBS buffer was injected subcutaneously into four mice per group. Tumor size was measured using an electronic digital caliper every week for 9 weeks.
Statistical analysis
All data are presented as the mean ± standard deviation. Statistical analyses were performed using the SPSS statistical software program. P values were obtained using an unpaired two-tailed t-test, and P < 0.05 was considered statistically significant.
Results
Drp1 expression in human cancer tissue arrays
To investigate the role of Drp1 in tumorigenesis, we first compared the abundance of Drp1 in human cancers with corresponding normal tissues using multiple cancer tissue microarrays. For more precise quantitative measurement, Drp1 levels were assessed by immunofluorescence staining analysis using a confocal microscope and analysis software. Immunofluorescence intensity analysis of Drp1 in four different types of cancer tissues showed that protein levels of Drp1 were significantly lower in colon and lung cancer tissues than in normal tissues, whereas Drp1 protein levels in breast and prostate cancer tissues were similar to those in normal tissues (Fig. 1A) . Quantitative analysis of the Drp1 immunofluorescence signal revealed that the Drp1 levels of colon cancer tissues were 40.8% of those in normal tissues, and the Drp1 levels in lung tissues were 64% of those in adjacent normal tissues (Fig. 1B) . These results suggest that reduced expression of Drp1 may be associated with colon and lung cancers.
Drp1 is downregulated in human colon tissues
To further confirm the decrease in Drp1 in colon cancer, we examined Drp1 expression in a colon cancer tissue array containing 12 matched pairs of colon cancer and adjacent normal tissues ( Fig. 2A) . Interestingly, quantitative analysis revealed that Drp1 levels were lower in tumor tissues than in normal adjacent tissues in nine pairs (75%), whereas in three pairs (25%), Drp1 expression was increased in tumor tissues compared with that in normal adjacent tissues (Fig. 2B) . The rate of decreased Drp1 levels was higher in male patients. Among eight male colon cancer patients, low levels of Drp1 were observed in tissues from seven (87.5%), whereas half of the colon cancer tissues revealed a decrease in Drp1 levels in female patients. The immunofluorescence signals did not differ significantly between total tumors and adjacent normal tissues (Fig. 2C) . Analysis of Drp1 expression based on tumor grade revealed that Drp1 expression in Grades I (well-differentiated) and II (moderately differentiated) tumor tissues is not significantly different from that in adjacent normal tissues. However, Drp1 expression in Grade III (poorly differentiated) tumor tissues is significantly reduced compared with that in well-differentiated adjacent normal tissues (P < 0.01) (Fig. 2D) . Drp1 expression in Grade III tumor tissues was decreased to 48.2% of the level observed in the adjacent normal tissues. These results suggest that decrease of Drp1 expression is specifically associated with high grade colon cancer.
Drp1 is downregulated in human lung cancer tissues
To examine the relationship between Drp1 expression and lung cancer, we also examined Drp1 expression in a non-small-cell lung cancer (NSCLC) tissue array containing 23 matched pairs of lung cancer and adjacent normal tissues (Fig. 3A) . Consistent with the results from the multiple cancer tissue microarrays, reduced expression of Drp1 was observed in 18 of 23 cancer tissues (78.3%). Low levels of Drp1 expression were observed in all NSCLC subtypes, including squamous cell carcinoma (90%), adenocarcinoma (72.7%), and large cell carcinoma (50%) (Fig. 3B) . Interestingly, as with colon cancer, reduced Drp1 levels were more frequently observed in male tissues. All male cancer tissues showed decreased Drp1 levels, whereas 6 of 11 female tissues (54.5%) showed Drp1 reduction.
The mean Drp1 level in total lung cancer tissues was approximately 66% of that in normal tissues, and the difference in Drp1 expression was statistically significant (P < 0.01) (Fig. 3C) . In addition, Drp1 expression was decreased in the advanced stage of lung cancer. While the Drp1 level in adenocarcinoma tissues was 71% of that in normal tissues, the Drp1 level was decreased to 31% in metastatic adenocarcinoma (Fig. 3D) . Collectively, these results suggest that decreased Drp1 levels are associated with the progression of lung cancer.
Reduction of Drp1 increases migration activity and tumor formation
The reduced expression of Drp1 in human colon and lung cancer tissues suggests that Drp1 may be involved in tumorigenesis. To examine the role of Drp1 loss in cancer, we generated Drp1-depleted cell lines by stably expressing shRNA against Drp1 (shDrp1) in the human NSCLC cell line A549. Western blotting analysis confirmed a significant reduction of Drp1 expression in A549 cells expressing shDrp1, whereas Drp1 expression in control shRNA-expressing cells (shNT) was comparable to that in the parental A549 cells ( Supplementary  Fig. S1A ). The effect of Drp1 knockdown was further confirmed by the increase in mitochondrial elongation (Supplementary Fig. S1B) .
To address the role of Drp1 in tumorigenesis, we first examined whether knockdown of Drp1 increases cellular proliferation. However, the cell growth of A549 cells expressing shDrp1 was comparable to that of control shRNA-expressing cells (shNT) (Fig. 4A,B) . Because we observed that Drp1 levels were further decreased in metastatic lung adenocarcinoma tissues, we next examined whether loss of Drp1 expression increases the invasive potential of lung cancer cells. We performed in vitro invasion and migration assays comparing Drp1 knockdown A549 cells with control cells. The invasion activity of Drp1 knockdown cells (shDrp1) was slightly increased (1.25-fold), but this The Drp1 levels in normal (n = 12), Grade I (n = 3), Grade II (n = 6), and Grade III (n = 3) tumor tissues in the tissue array were compared and plotted as the mean ± SD. **P < 0.01. NS, not significant. increase was not statistically significant (Fig. 4C) . However, as shown in Fig. 4D , the migration capacity of Drp1 knockdown cells was significantly increased by 2.25-fold compared with that of nontransfected A549 cells. These results indicate that the decrease in Drp1 confers increased migration potential in human NSCLC cells, which may contribute to lung cancer progression.
To validate the relevance of the in vitro migration assay results, we further examined the effect of Drp1 depletion using a tumor xenograft mouse model. NOD/SCID mice were subcutaneously inoculated with either Drp1-depleted bladder carcinoma EJ cells (shDrp1) or control EJ cells (shGFP) (Supplementary Fig. S1C) . Initially, the growth rates of tumors derived from the two cell lines were similar. However, the tumors derived from EJ-shDrp1 cells were grew faster than the control tumors by 7 weeks after inoculation (Fig. 4E) . Upon termination of the study, the tumors from EJshDrp1 cells were significantly larger than the control tumors (140% compared with control tumors). These results further support that the loss of Drp1 enhances tumor development in vivo.
Discussion
In this study, we found that decreased Drp1 expression is associated with human cancers. Tissue array analysis revealed that the level of Drp1 was significantly reduced in colon and lung cancer samples. The decrease in Drp1 levels in colon and lung cancer was further confirmed in matched pairs of cancer and adjacent normal tissues. Importantly, we observed that the decrease in Drp1 expression was greater in advanced grades of both colon and lung cancer, suggesting that the loss of Drp1 expression may be involved in tumor progression. Consistent with this observation, knockdown of Drp1 increased the migration potential of human NSCLC cells in vitro and increased tumor formation in a mouse xenograft model. These results suggest that loss of Drp1 may play a role in the progression of human colon and lung cancer to malignant carcinoma.
In addition to a critical role in mitochondrial dynamics, recent studies have suggested that Drp1 function is associated with various cellular processes including autophagy, apoptosis, and necrosis [1, 10] . These studies indicate that the effects of Drp1 deficiency or mutation depend on the tissue or cell type, suggesting that a more careful approach is needed when studying the role of Drp1 in human diseases. Although several recent studies have reported upregulation of Drp1 expression in some human cancers [20, 21] , additional studies are needed to address the exact role of Drp1 function in tumorigenesis. In the present study, we observed decreased Drp1 expression in 18 of 23 samples (78.3%) of lung cancer patient tissue compared with expression in adjacent normal tissue. We also observed decreased Drp1 levels in nine of 12 colon cancer tissues (75%) compared with levels in adjacent normal tissue. These results differ from those of previous studies and suggest that the effects of changes in Drp1 expression may depend on cell type and physiological context. Consistent with this notion, we did not observe a reduction of cell proliferation in Drp1-depleted A549 lung cancer cells, whereas decreased proliferation and enhanced apoptosis upon Drp1 depletion has been observed in colon cancer cells [24] . Interestingly, tumors derived from Drp1-depleted cancer cells were larger than tumors derived from control cells, although the tumor growth rates were similar at the early phase. These results suggest that reduced (C) Average Drp1 expression in total lung cancer and matched adjacent tissues was calculated and plotted as the mean ± SD. (D) Drp1 levels in normal lung tissues (n = 11), adenocarcinoma (adenoc., n = 15), and metastatic adenocarcinoma (metastatic adenoc., n = 6) tissues in the tissue array were compared and plotted as the mean ± SD. *P < 0.05, **P < 0.01.
Drp1 contributes to the later phase of tumor progression in human lung cancer cells rather than initial tumor growth.
How the reduction of Drp1 contributes to tumor progression is an important question arising from the present study. Drp1 has been shown to participate in programmed cell death. Interestingly, developmental apoptosis of neural crest cells was decreased in Drp1 KO embryos [16] , whereas apoptosis in the neuroepithelium of brain was increased [15] . These results suggest that Drp1 plays various roles in apoptosis depending on cell type and physiological context. The loss of Drp1 may confer resistance to apoptosis in some cancer cells, thus promoting tumor formation or cancer progression. Whether Drp1 deficiency increases resistance to apoptosis in human colon and lung cancer cells remains to be explored.
Qian et al. recently demonstrated that loss of Drp1 induces not only mitochondria hyperfusion but also centrosome overamplification and chromosomal instability [25] . The authors also found that the induction of aneuploidy in Drp1-deficient cells is not due to defective mitochondrial energy metabolism. These results suggest that loss of Drp1 could induce various cellular dysfunctions by independently modulating several processes, such as the cell cycle checkpoint, centrosome replication and mitochondrial function. Drp1 reduction might promote tumor progression by increasing genomic instability, which plays an important role in cancer progression. Imbalanced mitochondrial dynamics is often observed in various human cancers and has been implicated in tumorigenesis and cancer progression [4, 26] . Mitochondrial remodeling and the shift in energy production from oxidative phosphorylation to glycolysis, known as the Warburg effect, play important roles in tumor development [4] . Parone et al. [27] reported that Drp1 reduction leads to mitochondrial dysfunction, such as decreased mitochondrial respiration and loss of mitochondrial DNA. Whether decreased Drp1 contributes to the metabolic conversion required for cancer development remains to be explored in the future. We also noted an association of decreased Drp1 with gender. The decreased Drp1 levels were observed at much higher frequency in cells (shDrp1) (n = 4) was measured once per week for 9 weeks. The data provided represent the mean ± SD calculated for each group. *P < 0.05 compared with A549 cells. NS, not significant.
males among both lung and colon cancer patients. Analyzing the effects of various genetic and physiological factors known to contribute to gender differences in cancer may facilitate the elucidation of the molecular mechanism underlying the decrease in Drp1 [28] .
In conclusion, our findings suggest that decreased Drp1 expression is associated with human colon and lung cancer. The present study also provides evidence that loss of Drp1 increases migration potential and tumor formation in vivo. Although the precise mechanism by which the decrease in Drp1 contributes to colon and lung cancer remains to be explored, our results indicate a pleotropic role of Drp1 in cancer development. Further clinical and basic studies will reveal the exact role of Drp1 in different human cancers and facilitate the development of more efficient therapeutic and diagnostic strategies based on Drp1.
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